Patents by Inventor Carol Pearcy Howard

Carol Pearcy Howard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7115378
    Abstract: A method for identifying and quantifying peptides resulting from enzyme cleavage of collagen type II by mass spectrometric analysis to detect characteristic peptide fragments of a carboxy-terminus having known mass to charge ratios to identify the peptide having that carboxy-terminus. Identification and quantification of the peptides in a biological sample is used to assess activity of proteolytic enzymes in diseases or physiological conditions such as osteoarthritis and rheumatoid arthritis and to assess the efficacy of enzyme blocking agents.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: October 3, 2006
    Assignee: Pharmacia Corporation
    Inventors: Dean J. Welsch, Kevin L. Duffin, Olga V. Nemirovskiy, Dawn R. Dufield, Teresa Sunyer, Carol Pearcy Howard
  • Publication number: 20040048852
    Abstract: A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrido or R1 and R2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical.
    Type: Application
    Filed: January 7, 2003
    Publication date: March 11, 2004
    Inventors: Thomas E. Barta, Daniel P. Becker, Terri L. Boehm, Gary A. DeCrezcenzo, John N. Freskos, Daniel P. Getman, Joseph J. McDonald, Clara I. Villamil, Louis John Bedell, Jeffery N. Carroll, Theresa R. Fletcher, Susan Landis Hockerman, Stephen A. Kolodziej, Madeleine H. Li, Deborah A. Mischke, Patrick B. Mullins, Carol Pearcy Howard, Joseph Gerace Rico, Nathan W. Stehle
  • Patent number: 6683093
    Abstract: This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrecanase activity. This invention also is directed to a treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP activity and/or aggrecanase activity.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: January 27, 2004
    Assignee: Pharmacia Corporation
    Inventors: Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, Jeffery N. Carroll, Gary A. DeCrescenzo, Yvette M. Fobian, John N. Freskos, Daniel P. Getman, Joseph J. McDonald, Madeleine H. Li, Susan L. Hockerman, Carol Pearcy Howard, Steve A. Kolodziej, Deborah A. Mischke, Joseph G. Rico, Nathan W. Stehle, Michael B. Tollefson, William F. Vernier, Clara I. Villamil, Darren J. Kassab
  • Publication number: 20030073718
    Abstract: This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrecanase activity. This invention also is directed to a treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP activity and/or aggrecanase activity.
    Type: Application
    Filed: November 21, 2001
    Publication date: April 17, 2003
    Inventors: Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, Jeffery N. Carroll, Gary A. DeCrescenzo, Yvette M. Fobian, John N. Freskos, Daniel P. Getman, Joseph J. McDonald, Madeleine H. Li, Susan L. Hockerman, Carol Pearcy Howard, Steve A. Kolodziej, Deborah A. Mischke, Joseph G. Rico, Nathan W. Stehle, Michael B. Tollefson, William F. Vernier, Clara I. Villamil, Darren J. Kassab
  • Publication number: 20030054426
    Abstract: A method for identifying and quantifying peptides resulting from enzyme cleavage of collagen type II by mass spectrometric analysis to detect characteristic peptide fragments of a carboxy-terminus having known mass to charge ratios to identify the peptide having that carboxy-terminus. Identification and quantification of the peptides in a biological sample is used to assess activity of proteolytic enzymes in diseases or physiological conditions such as osteoarthritis and rheumatoid arthritis and to assess the efficacy of enzyme blocking agents.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 20, 2003
    Inventors: Dean J. Welsch, Kevin L. Duffin, Olga V. Nemirovskiy, Dawn R. Dufield, Teresa Sunyer, Carol Pearcy Howard
  • Publication number: 20030049715
    Abstract: A method for identifying and quantifying peptides resulting from enzyme cleavage of collagen type II by mass spectrometric analysis to detect characteristic peptide fragments of a carboxy-terminus having known mass to charge ratios to identify the peptide having that carboxy-terminus. Identification and quantification of the peptides in a biological sample is used to assess activity of proteolytic enzymes in diseases or physiological conditions such as osteoarthritis and rheumatoid arthritis and to assess the efficacy of enzyme blocking agents.
    Type: Application
    Filed: September 3, 2002
    Publication date: March 13, 2003
    Inventors: Dean J. Welsch, Kevin L. Duffin, Olga V. Nemirovskiy, Dawn R. Dufield, Teresa Sunyer, Carol Pearcy Howard